Physician profile
Howard J Snapper
NPI 1427019165
$30,285.39
in general payments reported to CMS, 2019-2025
40 companies · $5,117 in 2025
The $5,117 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,573 · 2021: $493 · 2022: $908 · 2023: $1,168 · 2024: $1,193 · 2025: $5,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,757 · Consulting Fee: $3,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,757.27 |
| Consulting Fee | $3,720.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $12,840.05 | 2019-2020 | |
| Akcea Therapeutics, INC. | $5,862.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $4,377.83 | 2019-2025 | Wainua, Brilinta, Onglyza |
| Novartis Pharmaceuticals Corporation | $1,347.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $569.35 | 2021-2025 | Verquvo, Winrevair |
| Pfizer INC. | $539.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $524.65 | 2019-2024 | Xarelto |
| Amgen INC. | $375.18 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.38 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $299.39 | 2019-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $283.69 | 2022-2025 | Amvuttra |
| W. L. Gore & Associates, INC. | $257.20 | 2019-2021 | |
| Medtronic, INC. | $254.78 | 2021-2024 | Symplicity G3, Onyx Frontier |
| Amarin Pharma, INC. | $245.91 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $236.26 | 2019-2025 | Uptravi, Opsumit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Snapper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.